Granahan Investment Management Trims Exact Sciences Holdings

Institutional investor reduces stake in medical research company by 12.6% in Q3

Mar. 16, 2026 at 10:39am

Got story updates? Submit your updates here. ›

Granahan Investment Management LLC, a major institutional investor, has reduced its position in Exact Sciences Corporation (NASDAQ:EXAS) by 12.6% in the third quarter of 2026. The fund now owns 281,918 shares of the medical research company's stock, down from 322,507 shares previously.

Why it matters

Institutional investors like Granahan closely monitor and frequently adjust their holdings in public companies. This move by Granahan suggests a potential shift in sentiment or outlook regarding Exact Sciences, which could impact the stock price and market perceptions of the company.

The details

According to a recent 13F filing with the SEC, Granahan Investment Management sold 40,589 shares of Exact Sciences stock during the third quarter. The firm now owns approximately 0.15% of Exact Sciences' outstanding shares, valued at $15.4 million as of the filing date.

  • Granahan Investment Management filed its 13F report for the third quarter of 2026.

The players

Granahan Investment Management LLC

An institutional investment management firm that owns stakes in various public companies.

Exact Sciences Corporation

A medical research company focused on early cancer detection and prevention, best known for its Cologuard colorectal cancer screening test.

Got photos? Submit your photos here. ›

The takeaway

This reduction in Granahan's Exact Sciences holdings could signal a shift in the investment firm's outlook on the company, though the reasons behind the move are not entirely clear. Investors will likely be watching to see if other major institutional investors follow suit or maintain their positions in Exact Sciences.